You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Induction with rituximab and ATG

Showing 1 - 25 of 6,661
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

CNS Lymphoma Trial in China (Selinexor, Rituximab, Methotrexate)

Not yet recruiting
  • Central Nervous System Lymphoma
  • Hefei, Anhui, China
  • +4 more
Jan 26, 2023

De Novo Kidney Transplant Patients Trial in China (ATG-F)

Completed
  • De Novo Kidney Transplant Patients
  • Beijing, China
  • +13 more
Jul 26, 2022

Lymphoid Leukemia, Small Lymphocytic Lymphoma, Lymphoma, Non-Hodgkin Trial in Madison (Bendamustine, Rituximab, Lenalidomide)

Completed
  • Lymphoid Leukemia
  • +2 more
  • Madison, Wisconsin
    University of Wisconsin
Jan 30, 2023

DLBCL Germinal Center B-Cell Type Trial in China (Selinexor, Rituximab, Cyclophosphamide)

Recruiting
  • DLBCL Germinal Center B-Cell Type
  • Guangzhou, Guangdong, China
  • +5 more
Aug 16, 2022

Pediatric Induction Therapy in Kidney Transplantation

Completed
  • Kidney Transplant Rejection
  • Pediatric Kidney Disease
  • Basiliximab Injection
  • rabbit ATG
  • Guangzhou, Guangdong, China
  • +4 more
Oct 15, 2023

Patients Receiving Mismatched Allogeneic HCT Trial in Germany (immunosuppression)

Terminated
  • Patients Receiving Mismatched Allogeneic HCT
  • Mainz, Germany
  • +3 more
Jun 29, 2022

REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS Trial in Paris Cedex 10 (Autologous Hematopoietic Stem Cell Transplantation, Rituximab)

Withdrawn
  • REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS
  • Autologous Hematopoietic Stem Cell Transplantation
  • Rituximab
  • Paris Cedex 10, France
    Dept. of Internal Medicine, Hôpital Saint-Louis
Sep 21, 2021

Multiple Sclerosis, Relapsing-Remitting Trial in La Jolla (Autologous hematopoietic stem cell transplantation,

Recruiting
  • Multiple Sclerosis, Relapsing-Remitting
  • Autologous hematopoietic stem cell transplantation
  • +2 more
  • La Jolla, California
    Scripps Green Hospital
Aug 16, 2022

B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Recurrent B Acute

Recruiting
  • B Acute Lymphoblastic Leukemia
  • +2 more
  • Portland, Oregon
    OHSU Knight Cancer Institute
Dec 16, 2022

Interstitial Lung Disease, Scleroderma Trial in Assiut (Rituximab, IL6 inhibitor)

Completed
  • Interstitial Lung Disease
  • Scleroderma
  • Assiut, Yes, Egypt
    Manal Hassanien
Jul 18, 2023

Mantle Cell Lymphoma Trial in Seoul (RB/RBAC alternating, RB)

Not yet recruiting
  • Mantle Cell Lymphoma
  • RB/RBAC alternating
  • RB
  • Seoul, Gangnam-Gu, Korea, Republic of
    Samsung Medical Center
Apr 18, 2022

Kidney Failure, Chronic, Renal Insufficiency Trial in Boston (drug, radiation, procedure)

Completed
Has Results
  • Kidney Failure, Chronic
  • Renal Insufficiency
  • Boston, Massachusetts
    Massachusetts General Hospital
Oct 4, 2021

CNS Lymphoma, DLBCL Trial in United States (Lenalidomide, Methotrexate, Nivolumab)

Recruiting
  • Central Nervous System Lymphoma
  • Diffuse Large B-Cell Lymphoma
  • Los Angeles, California
  • +42 more
Jan 26, 2023

Follicular Lymphoma, Relapsed and Refractory Follicular Lymphoma Trial in Guangzhou (Orelabrutinib and Rituximab, Orelabrutinib)

Recruiting
  • Follicular Lymphoma
  • Relapsed and Refractory Follicular Lymphoma
  • Guangzhou, Guangdong, China
  • +2 more
Mar 23, 2022

Refractory Non Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma Trial in Sacramento (biological, radiation, procedure, drug)

Active, not recruiting
  • Refractory Non Hodgkin Lymphoma
  • Relapsed Non Hodgkin Lymphoma
  • rituximab
  • +7 more
  • Sacramento, California
    University of California Davis
Nov 28, 2022

Primary CNS Lymphoma Trial in Stuttgart (Experimental Treatment: one course Rituximab/HD-Methotrexate, two courses of MATRix,

Recruiting
  • Primary Central Nervous System Lymphoma
  • Experimental Treatment: one course Rituximab/HD-Methotrexate, two courses of MATRix
  • Control intervention: four courses of MATRix
  • Stuttgart, Baden-Württemberg, Germany
    Klinikum Stuttgart
Feb 15, 2022

Lung Transplant Trial in United States (Rituximab (Rituxan®), Placebo)

Completed
Has Results
  • Lung Transplant
  • Rituximab (Rituxan®)
  • Placebo
  • Palo Alto, California
  • +6 more
Oct 7, 2021

Sickle Cell Disease, Thalassemia, Beta, Thalassemia Trial in United States (Fludarabine, Cyclophosphamide, Tacrolimus)

Recruiting
  • Sickle Cell Disease
  • +2 more
  • Basking Ridge, New Jersey
  • +5 more
Feb 17, 2023

Stem Cell Transplantation Trial in Houston (Fludarabine, Dexamethasone, Cyclophosphamide)

Not yet recruiting
  • Stem Cell Transplantation
  • Houston, Texas
    M D Anderson Cancer Center
May 4, 2022

Lupus Nephritis Trial in Bucharest (Rituximab, Mycophenolate Mofetil, Cyclophosphamide)

Recruiting
  • Lupus Nephritis
  • Bucharest, Romania
    Fundeni Clinical Institute
Mar 2, 2022

Hematopoietic Cell Transplantation Recipient, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in

Active, not recruiting
  • Hematopoietic Cell Transplantation Recipient
  • +3 more
  • Allogeneic Bone Marrow Transplantation
  • +10 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 18, 2022

Hematologic Malignancies Trial in Chicago, New York (device, drug, radiation)

Recruiting
  • Hematologic Malignancies
  • CliniMACS® CD34 Reagent System
  • +7 more
  • Chicago, Illinois
  • +1 more
Sep 20, 2022

Transplant Rejection Trial in Worldwide (BIVV020, Intravenous immunoglobulin (IVIg), Rituximab)

Recruiting
  • Transplant Rejection
  • Westmead, New South Wales, Australia
  • +14 more
Aug 2, 2022

Eosinophilic Granulomatosis With Polyangiitis (EGPA) Trial in Paris (Rituximab, Placebo-rituximab, Cyclophosphamide)

Completed
  • Eosinophilic Granulomatosis With Polyangiitis (EGPA)
  • Paris, France
    Hôpital Cochin
Apr 13, 2021

Follicular Lymphoma Trial in Shanghai (BR for 6 cycles +R for 8 cycles, RCHOP for 6 cycles +R for 8 cycles, R2 for 6 cycles + R2

Recruiting
  • Follicular Lymphoma
  • BR for 6 cycles +R for 8 cycles
  • +2 more
  • Shanghai, China
    Ruijin Hospital
Apr 10, 2021